Black Box and Nokia Team Up to Create OnGo Private Wireless/CBRS Network for Industry 4.0
Black Box, a leading global solutions integrator, announced today that it has joined with industry wireless communications innovator Nokia to provide the most complete, next-generation OnGo® private wireless/CBRS network for Industry 4.0. The partnership allows Black Box to drive innovation in connectivity and the adoption of private networks, giving the industrial manufacturing market superior options for wireless networking. Black Box explains that OnGo® — an even-licensed, low-band wireless spectrum that gives manufacturers access to private wireless connectivity at a fraction of the cost associated with LTE — mirrors the simplicity of Wi-Fi while providing secure, cost-effective LTE coverage for enterprise wireless traffic and IoT applications.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211103005142/en/
“Nokia welcomes Black Box to our Global Partner Program to help meet growing demand for private 4G/5G campus networks,” said Vikas Trehan, vice president, channels and alliances for Nokia. “Black Box’s intimate knowledge and trusted relationships within these enterprise campus networks, combined with world-class products and services from Nokia, will help realize the Industry 4.0 vision.”
“Private wireless and emerging private 5G networks are poised to redefine the corporate wireless networking space. Large campuses and sites like airports and large logistics and distribution hubs are pushing current WLAN standards to their technological limits,” said Bill Holman, vice president and general manager of 5G technologies at Black Box. “Thanks to our partnership with Nokia, sites like those can now break free from the limitations of WLAN and get exactly the wireless connectivity they need.”
Black Box designs, builds, and manages a full range of wireless technologies to support connected enterprise, delivering digital workplace connectivity across multiple industries. Leading manufacturers turn to Black Box to help incorporate OnGo® and 5G into their existing and future wireless networks. With Nokia Digital Automation Cloud (DAC) end-to-end private wireless, Black Box helps clients realize the full potential of Industry 4.0.
Further information about Black Box and the company’s global solutions integration services offerings is available at www.blackbox.com.
About Nokia
As a trusted partner for critical networks, we are committed to innovation and technology leadership across mobile, fixed and cloud networks with intellectual property and long-term research led by the award-winning Nokia Bell Labs. Nokia Digital Automation Cloud is a high-performance, LTE/5G end-to-end private wireless networking and edge computing platform. Delivering secure, plug and play, reliable wireless connectivity, Nokia DAC enables industrial use-cases leveraging real-time data for smart manufacturing, predictive maintenance, remote operations and Industrial Internet of Things (IoT) opportunities.
About Black Box
Black Box® is a trusted IT solutions provider delivering cutting-edge technology solutions and world-class consulting services to businesses on every continent. The breadth of our global reach and depth of expertise accelerate customer success by bringing people, ideas, and technology together to solve real-world business problems. Our IT infrastructure solutions, services, and products enable secure, flawless connectivity and meaningful collaboration across town or around the globe.
Black Box is a wholly owned subsidiary of AGC Networks. To learn more, visit the Black Box website at www.blackbox.com. Follow the company on Twitter @BlackBox_ns. Black Box® and the Double Diamond logo are registered trademarks of BB Technologies Inc.
All other trademarks referenced herein are the property of their respective owners.
PR Link: www.wallstcom.com/BlackBox/211103-Black_Box-Nokia_Partnership.docx
Photo: www.wallstcom.com/BlackBox/BlackBox-Nokia_OnGo-Private_Wireless_Network.jpg
Black Box and Nokia Team Up to Create OnGo® Private Wireless/CBRS Network for Industry 4.0
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211103005142/en/
Contact information
Black Box:
Cristine Kimbrel
Sr. Product Manager | 5G & OnGo
+1.724.873.7044
cristine.kimbrel@BlackBox.com
Nokia:
Evan Forrest
Global Industrial Partner Manager for Nokia
+1.925.413.0015
evan.forrest@nokia.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 11:00:00 EET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 11:00:00 EET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 10:00:00 EET | Press release
Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity. Pimicotinib, a colony stimulating factor-1 receptor (CSF-1R) inhibitor developed by Abbisko Therapeutics Co., Ltd., Shanghai, China, is the first Chemical Drug Class 1 approved in China for the treatment of TGCT. “We are continuing to deliver on our commitment to improving the lives of patients with rare tumors with this first-in-the-world regulatory approval of pimicotinib,” said Danny Bar-Zohar, CEO Healthcare and Member of the Executive Board of Merck. “This approval is a significant step forward in further strengthening our leadership in rare tumors, while offering patients the opportunity to change the course of
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 09:44:00 EET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom